H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on the shares following the Q3 report. The firm says new clinical data support the thesis that elironrasib addresses resistance mechanisms to first-generation KRAS inhibitors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines Reports Q3 2025 Financial Results
- Revolution Medicines: Strategic Advancements and Promising Pipeline in PDAC Treatment Justify Buy Rating
- Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements
- Revolution Medicines reiterates FY25 GAAP net loss guidance
- Revolution Medicines reports Q3 EPS ($1.61), consensus ($1.41)